Patrick A Flume

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3142683/publications.pdf

Version: 2024-02-01

118 papers	8,343 citations	81900 39 h-index	46799 89 g-index
120 all docs	120 docs citations	120 times ranked	6106 citing authors

#	Article	IF	Citations
1	Voice and Respiratory Characteristics of Men and Women Seeking Treatment for Presbyphonia. Journal of Voice, 2022, 36, 673-684.	1.5	6
2	Respiratory Muscle Strength Training to Improve Vocal Function in Patients with Presbyphonia. Journal of Voice, 2022, 36, 344-360.	1.5	16
3	Disease burden in people with cystic fibrosis heterozygous for F508del and a minimal function mutation. Journal of Cystic Fibrosis, 2022, 21, 96-103.	0.7	2
4	Improvements in anthropometric measures and gastrointestinal tolerance in patients with cystic fibrosis by using a digestive enzyme cartridge with overnight enteral nutrition. Nutrition in Clinical Practice, 2022, 37, 344-350.	2.4	7
5	Time-to-positivity of Mycobacterium avium complex in broth culture associates with culture conversion. BMC Infectious Diseases, 2022, 22, 246.	2.9	6
6	Health care costs in a randomized trial of antimicrobial duration among cystic fibrosis patients with pulmonary exacerbations. Journal of Cystic Fibrosis, 2022, , .	0.7	2
7	From the Editor's Desk. Journal of Cystic Fibrosis, 2022, 21, 197-198.	0.7	0
8	Obesity in Cystic fibrosis: prevalence, trends and associated factors data from the US cystic fibrosis foundation patient registry. Journal of Cystic Fibrosis, 2022, 21, 777-783.	0.7	22
9	A case report of CFTR modulator administration via carrier mother to treat meconium ileus in a F508del homozygous fetus. Journal of Cystic Fibrosis, 2022, 21, 721-724.	0.7	34
10	Antimicrobial resistance: Concerns of healthcare providers and people with CF. Journal of Cystic Fibrosis, 2021, 20, 407-412.	0.7	13
11	Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with cystic fibrosis. Journal of Cystic Fibrosis, 2021, 20, 78-85.	0.7	35
12	Changes in symptom scores as a potential clinical endpoint for studies of cystic fibrosis pulmonary exacerbation treatment. Journal of Cystic Fibrosis, 2021, 20, 36-38.	0.7	7
13	Development of Drugs for Nontuberculous Mycobacterial Disease. Chest, 2021, 159, 537-543.	0.8	9
14	JCF Year in Review. Journal of Cystic Fibrosis, 2021, 20, 1-2.	0.7	0
15	Managing the risks and benefits of clinical research in response to a pandemic. Journal of Clinical and Translational Science, 2021, 5, .	0.6	4
16	Efficacy and safety of inhaled dry-powder mannitol in adults with cystic fibrosis: An international, randomized controlled study. Journal of Cystic Fibrosis, 2021, 20, 1003-1009.	0.7	7
17	Ototoxicity in cystic fibrosis patients receiving intravenous tobramycin for acute pulmonary exacerbation. Journal of Cystic Fibrosis, 2021, 20, 288-294.	0.7	10
18	Prioritizing Studies of COVID-19 and Lessons Learned. Journal of Clinical and Translational Science, 2021, 5, 1-27.	0.6	8

#	Article	IF	Citations
19	Comparative analysis of antibodies to SARS-CoV-2 between asymptomatic and convalescent patients. IScience, 2021, 24, 102489.	4.1	11
20	Pulmonary Complications in Cystic Fibrosis: Past, Present, and Future. Chest, 2021, 160, 1232-1240.	0.8	8
21	Hospitalization Risk for Medicare Beneficiaries With Nontuberculous Mycobacterial Pulmonary Disease. Chest, 2021, 160, 2042-2050.	0.8	3
22	Amikacin Liposome Inhalation Suspension for Mycobacterium avium Complex Lung Disease: A 12-Month Open-Label Extension Clinical Trial. Annals of the American Thoracic Society, 2021, 18, 1147-1157.	3.2	29
23	Alterations of lipid metabolism provide serologic biomarkers for the detection of asymptomatic versus symptomatic COVID-19 patients. Scientific Reports, 2021, 11, 14232.	3.3	28
24	Management of chronic Pseudomonas aeruginosa infection with inhaled levofloxacin in people with cystic fibrosis. Future Microbiology, 2021, 16, 1087-1104.	2.0	7
25	Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Lung Disease. Chest, 2021, 160, 831-842.	0.8	24
26	Clinical care for cystic fibrosis: preparing for the future now. Lancet Respiratory Medicine,the, 2020, 8, 10-12.	10.7	5
27	Predictors of pulmonary exacerbation treatment in cystic fibrosis. Journal of Cystic Fibrosis, 2020, 19, 407-414.	0.7	15
28	Antimicrobial resistance in cystic fibrosis: A Delphi approach to defining best practices. Journal of Cystic Fibrosis, 2020, 19, 370-375.	0.7	24
29	Treatment of pulmonary exacerbations in cystic fibrosis. Current Opinion in Pulmonary Medicine, 2020, 26, 679-684.	2.6	11
30	Seven P's of publication practices. Journal of Cystic Fibrosis, 2020, 19, 333-335.	0.7	3
31	Leveraging early markers of cystic fibrosis structural lung disease to improve outcomes. European Respiratory Journal, 2020, 55, 2000105.	6.7	1
32	Overcoming non-compliance with clinical trial registration and results reporting: One Institution's approach. Contemporary Clinical Trials Communications, 2020, 18, 100557.	1.1	9
33	JCF Year in Review. Journal of Cystic Fibrosis, 2020, 19, 505-506.	0.7	0
34	Pursuit of Equity. Journal of Cystic Fibrosis, 2020, 19, 171.	0.7	0
35	Screening practices for nontuberculous mycobacteria at US cystic fibrosis centers. Journal of Cystic Fibrosis, 2020, 19, 569-574.	0.7	12
36	Is bronchiectasis really a disease?. European Respiratory Review, 2020, 29, 190051.	7.1	10

#	Article	IF	Citations
37	Finding the relevance of antimicrobial stewardship for cystic fibrosis. Journal of Cystic Fibrosis, 2020, 19, 511-520.	0.7	18
38	1468. Culture Conversion and Mortality in Patients With Mycobacterium abscessus (MAB) Lung Disease: A Systematic Literature Review. Open Forum Infectious Diseases, 2020, 7, S736-S736.	0.9	1
39	1488. Relationship Between Culture Conversion and Clinical Outcomes in Patients With Mycobacterium abscessus (MAB) Lung Disease: A Systematic Literature Review. Open Forum Infectious Diseases, 2020, 7, S746-S746.	0.9	1
40	A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11â€¯years with cystic fibrosis. Journal of Cystic Fibrosis, 2019, 18, 708-713.	0.7	44
41	Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet, The, 2019, 394, 1940-1948.	13.7	804
42	Pulmonary Complications of Cystic Fibrosis. Seminars in Respiratory and Critical Care Medicine, 2019, 40, 804-809.	2.1	21
43	Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: A systematic review. Journal of Cystic Fibrosis, 2019, 18, 236-243.	0.7	84
44	The study of CFTR modulators in the very young. Lancet Respiratory Medicine,the, 2019, 7, 287-289.	10.7	1
45	Developing Inhaled Antibiotics in Cystic Fibrosis: Current Challenges and Opportunities. Annals of the American Thoracic Society, 2019, 16, 534-539.	3.2	33
46	Rheumatoid arthritis-associated bronchiectasis â€“ Authors' reply. Lancet, The, 2019, 393, 2036.	13.7	3
47	Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections. Clinical Infectious Diseases, 2019, 69, 1812-1816.	5.8	62
48	JCF â€“ progress in 2018. Journal of Cystic Fibrosis, 2019, 18, 1-5.	0.7	0
49	Disruption in research publishing â€“ the open access revolution. Journal of Cystic Fibrosis, 2019, 18, 747-749.	0.7	4
50	Cystic Fibrosis: Advances in Understanding and Treatment. Seminars in Respiratory and Critical Care Medicine, 2019, 40, 699-700.	2.1	0
51	Measuring recovery in health-related quality of life during and after pulmonary exacerbations in patients with cystic fibrosis. Journal of Cystic Fibrosis, 2019, 18, 737-742.	0.7	22
52	Pediatric and Adult Recommendations Vary for Sibling Testing in Cystic Fibrosis. Journal of Genetic Counseling, 2018, 27, 1049-1054.	1.6	4
53	ECFS best practice guidelines: the 2018 revision. Journal of Cystic Fibrosis, 2018, 17, 153-178.	0.7	521
54	Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CF. Contemporary Clinical Trials, 2018, 64, 35-40.	1.8	42

#	Article	IF	Citations
55	Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor. Journal of Cystic Fibrosis, 2018, 17, 83-88.	0.7	36
56	Regulatory Support Improves Subsequent IRB Approval Rates in Studies Initially Deemed Not Ready for Review: A CTSA Institutionâ€™s Experience. Journal of Empirical Research on Human Research Ethics, 2018, 13, 139-144.	1.3	9
57	Defining antimicrobial resistance in cystic fibrosis. Journal of Cystic Fibrosis, 2018, 17, 696-704.	0.7	66
58	Antimicrobial resistance in cystic fibrosis: Does it matter?. Journal of Cystic Fibrosis, 2018, 17, 687-689.	0.7	18
59	Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity. Lancet, The, 2018, 392, 880-890.	13.7	247
60	Benefits of set length antibiotic treatment for pulmonary exacerbations. Lancet Respiratory Medicine,the, 2018, 6, 575-577.	10.7	0
61	In Vitro Activity of Ceftolozane/Tazobactam vs Nonfermenting, Gram-Negative Cystic Fibrosis Isolates. Open Forum Infectious Diseases, 2018, 5, ofy158.	0.9	20
62	Mycobacterial Disease: Evolving Concepts. Seminars in Respiratory and Critical Care Medicine, 2018, 39, 269-269.	2.1	0
63	Unmet needs in cystic fibrosis: the next steps in improving outcomes. Expert Review of Respiratory Medicine, 2018, 12, 585-593.	2.5	17
64	â€œPathogen Eradicationâ€•and â€œEmerging Pathogensâ€• Difficult Definitions in Cystic Fibrosis. Journal of Clinical Microbiology, 2018, 56, .	3.9	6
65	Providing Restricted Access to an Electronic Medical Record for Research Monitoring. Clinical Researcher, 2018, 32, .	0.5	0
66	Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR. Journal of Cystic Fibrosis, 2017, 16, 371-379.	0.7	46
67	Treatment decisions for MRSA in patients with cystic fibrosis (CF): when is enough, enough?. Thorax, 2017, 72, 297-299.	5.6	7
68	The challenges of maintaining momentum in CF drug development and approval - Commentary. Journal of Cystic Fibrosis, 2017, 16, 170-171.	0.7	1
69	Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations. Journal of Cystic Fibrosis, 2017, 16, 600-606.	0.7	76
70	Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations. Journal of Cystic Fibrosis, 2017, 16, 592-599.	0.7	69
71	Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. European Respiratory Journal, 2017, 49, 1700051.	6.7	253
72	Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 814-823.	5.6	212

#	Article	IF	Citations
73	Bronchodilators in cystic fibrosis: a critical analysis. Expert Review of Respiratory Medicine, 2017, 11, 13-20.	2.5	10
74	Learningâ€™s from the Editors Desk â€“ 2017. Journal of Cystic Fibrosis, 2017, 16, 645-646.	0.7	0
75	Efficacy measures for clinical trials: A review series. Journal of Cystic Fibrosis, 2016, 15, 415.	0.7	1
76	Inhaled alpha 1 -proteinase inhibitor therapy in patients with cystic fibrosis. Journal of Cystic Fibrosis, 2016, 15, 227-233.	0.7	43
77	Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis. Journal of Cystic Fibrosis, 2016, 15, 809-815.	0.7	50
78	Oneâ€year safety and efficacy of tobramycin powder for inhalation in patients with cystic fibrosis. Pediatric Pulmonology, 2016, 51, 372-378.	2.0	18
79	A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients. Journal of Cystic Fibrosis, 2016, 15, 495-502.	0.7	59
80	Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Journal of Cystic Fibrosis, 2016, 15, 634-640.	0.7	40
81	Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis. Thorax, 2016, 71, 223-229.	5.6	53
82	The role of 2,4-dihydroxyquinoline (DHQ) inPseudomonas aeruginosapathogenicity. PeerJ, 2016, 4, e1495.	2.0	36
83	Early Life Growth Trajectories in Cystic Fibrosis are Associated with Pulmonary Function at Age 6 Years. Journal of Pediatrics, 2015, 167, 1081-1088.e1.	1.8	63
84	Optimising inhaled mannitol for cystic fibrosis in an adult population. Breathe, 2015, 11, 39-48.	1.3	20
85	A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients. Journal of Cystic Fibrosis, 2015, 14, 507-514.	0.7	62
86	Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. Lancet Respiratory Medicine,the, 2015, 3, 524-533.	10.7	197
87	Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis. Paediatric Respiratory Reviews, 2015, 16, 246-248.	1.8	5
88	Clinical applications of pulmonary delivery of antibiotics. Advanced Drug Delivery Reviews, 2015, 85, 1-6.	13.7	46
89	A Preliminary Quality of Life Questionnaire-Bronchiectasis. Chest, 2014, 146, 437-448.	0.8	66
90	Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Medicine,the, 2014, 2, 738-749.	10.7	172

#	Article	IF	Citations
91	European Cystic Fibrosis Society Standards of Care: Best Practice guidelines. Journal of Cystic Fibrosis, 2014, 13, S23-S42.	0.7	438
92	State of progress in treating cystic fibrosis respiratory disease. BMC Medicine, 2012, 10, 88.	5.5	58
93	Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation. Chest, 2012, 142, 718-724.	0.8	290
94	Treatment of lung infection in patients with cystic fibrosis: Current and future strategies. Journal of Cystic Fibrosis, 2012, 11, 461-479.	0.7	421
95	Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. Journal of Cystic Fibrosis, 2011, 10, 54-61.	0.7	284
96	Applying clinical outcome variables to appropriate aerosolized antibiotics for the treatment of patients with cystic fibrosis. Respiratory Medicine, 2011, 105, S18-S23.	2.9	14
97	Pneumothorax in cystic fibrosis. Current Opinion in Pulmonary Medicine, 2011, 17, 220-225.	2.6	21
98	Pharmacokinetics and Safety of MP-376 (Levofloxacin Inhalation Solution) in Cystic Fibrosis Subjects. Antimicrobial Agents and Chemotherapy, 2011, 55, 2636-2640.	3.2	63
99	Cystic Fibrosis Pulmonary Guidelines. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 298-306.	5.6	225
100	Loss of cilia alters airway epithelial cells and evokes an immune response. FASEB Journal, 2010, 24, 612.4.	0.5	0
101	Patient-reported pain and impaired sleep quality in adult patients with cystic fibrosis. Journal of Cystic Fibrosis, 2009, 8, 321-325.	0.7	37
102	Cystic Fibrosis Pulmonary Guidelines. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 802-808.	5.6	634
103	Smoothing the transition from pediatric to adult care: lessons learned. Current Opinion in Pulmonary Medicine, 2009, 15, 611-614.	2.6	26
104	Pulmonary Complications of Cystic Fibrosis. Respiratory Care, 2009, 54, 618-627.	1.6	120
105	Cystic fibrosis pulmonary guidelines: airway clearance therapies. Respiratory Care, 2009, 54, 522-37.	1.6	204
106	A role for aerosolized antibiotics. Pediatric Pulmonology, 2008, 43, S29-S34.	2.0	5
107	Making the Diagnosis of Cystic Fibrosis. American Journal of the Medical Sciences, 2008, 335, 51-54.	1.1	8
108	Cystic Fibrosis Pulmonary Guidelines. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 957-969.	5.6	773

#	Article	IF	Citations
109	Emergency Preparedness for the Chronically Ill. American Journal of Nursing, 2005, 105, 68-72.	0.4	8
110	Massive Hemoptysis in Cystic Fibrosis. Chest, 2005, 128, 729-738.	0.8	189
111	Pneumothorax in Cystic Fibrosis. Chest, 2005, 128, 720-728.	0.8	136
112	Transition programs in cystic fibrosis centers: Perceptions of team members. Pediatric Pulmonology, 2004, 37, 4-7.	2.0	67
113	Airway Clearance Techniques. Seminars in Respiratory and Critical Care Medicine, 2003, 24, 727-736.	2.1	9
114	Pneumothorax in Cystic Fibrosis. Chest, 2003, 123, 217-221.	0.8	57
115	The Rationale for Aerosolized Antibiotics. Pharmacotherapy, 2002, 22, 71S-79S.	2.6	34
116	Transition programs in cystic fibrosis centers: Perceptions of pediatric and adult program directors. Pediatric Pulmonology, 2001, 31, 443-450.	2.0	95
117	Hepatopulmonary syndrome occurring after orthotopic liver transplantation. Liver Transplantation, 2001, 7, 1081-1084.	2.4	13
118	A Pilot Study of the Efficacy of Constant-Infusion Ceftazidime in the Treatment of Endobronchial Infections in Adults with Cystic Fibrosis. Pharmacotherapy, 1999, 19, 620-626.	2.6	24